Third US approval for Roche's Vabysmo

Swiss pharma giant Roche (ROG: SIX) has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO).

This is the third indication for Vabysmo, the first bispecific antibody approved for the eye. Previous approvals have been granted by the FDA to treat neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Together, the three retinal conditions affect around 70 million people worldwide, and they are among the leading causes of vision loss.